Loading...
•
Jun 30, 2024
Mirum Pharmaceuticals Q2 2024 Earnings Report
Mirum Pharmaceuticals reported Q2 2024 financial results and provided a business update.
Key Takeaways
Mirum Pharmaceuticals reported second quarter global net product sales of $77.8 million, a 139% increase compared to the second quarter of 2023. The company is on track to achieve full-year guidance of $310 to $320 million. Positive interim results were reported for volixibat in VISTAS PSC and VANTAGE PBC studies. LIVMARLI received marketing authorization in Europe for the treatment of PFIC.
Second quarter global net product sales were $77.8 million, representing a 139% increase compared to Q2 2023.
LIVMARLI second quarter net sales were $47.2 million, representing 45% growth compared to Q2 2023.
CHOLBAM and CHENODAL second quarter net sales were $30.5 million.
Mirum had cash, cash equivalents and investments of $295.4 million as of June 30, 2024.
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Mirum Pharmaceuticals Revenue by Segment
Revenue by Segment
Product Sales, Net Revenue
CapyFin.comLicense and Other Revenue
CapyFin.comLIVMARLI Net Product Sales Revenue
CapyFin.comBile Acid Medicines Net Product Sales Revenue
CapyFin.com Forward Guidance
Mirum Pharmaceuticals is on track to achieve full-year guidance of $310 to $320 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income